Pacira BioSciences Formed Partnership With Molteni Farmaceutici
The agreement grants Molteni exclusive rights to distribute the pain management drug EXPAREL in Europe and the UK.
Updated on Oct. 6, 2026 in Business Strategy
Live Poll
Do you trust that pharmaceutical companies prioritize patient access to non-opioid pain management over profits?
Pacira BioSciences has entered a strategic partnership with Molteni Farmaceutici to expand the reach of its opioid-sparing postsurgical pain medication, EXPAREL. Under the deal, Molteni will oversee commercialization, market access, and regulatory efforts in the European Union and the United Kingdom.
Why it matters
The partnership aims to broaden international access to non-opioid pain management options while supporting Molteni Farmaceutici's long-term growth strategy. By outsourcing European commercialization, Pacira leverages the expertise of an established firm to enter new markets.
Molteni Farmaceutici brings 130 years of operational heritage to the agreement, while Pacira will continue to handle manufacturing. The partnership follows a corporate filing detailing recent employee equity grants, including 3,600 stock options priced at $25.21 per share.
The players
Pacira BioSciences
Based in Brisbane, Calif., this company specializes in non-opioid pain management and regenerative health solutions.
Molteni Farmaceutici
This established pharmaceutical firm has a 130-year history and focuses on developing and commercializing pain and addiction treatments.
Locust Walk
This firm provides strategic advisory services for life sciences companies seeking growth and partnership opportunities.
The details
Molteni Farmaceutici will manage the regulatory and commercial pathways for EXPAREL, with initial market launches targeted for Italy, Germany, Austria, and Poland. The company also intends to pursue regulatory approval for the drug in Switzerland, while Locust Walk served as the financial advisor for Pacira during the deal process.
Timeline
October 05, 2026: Pacira and Molteni Farmaceutici announced their strategic partnership.
2027: The first commercial sale of EXPAREL is expected to occur.
Market Landscape
This move represents a broader trend of pharmaceutical firms seeking to expand market adoption of non-opioid analgesics through regional partnerships. It positions Pacira to scale its international footprint by aligning with established European players rather than building a standalone infrastructure.
European patients and healthcare providers can expect expanded access to opioid-sparing pain management options following the planned 2027 product launch. The agreement does not immediately alter pricing for existing patients but sets the stage for future availability across major EU markets.
The takeaway
The partnership demonstrates how specialized pharmaceutical firms can use regional expertise to navigate complex international regulatory landscapes. Companies looking to implement similar strategies should focus on identifying partners with established market access and a clear regulatory track record.
Further reading
For more information on corporate partnerships and international expansion, visit our Business Strategy section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access to non-opioid pain management over profits?
